Center for Human Immunology

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications, trials & patents

Abstract

In response to the SARS-CoV-2 pandemic we have made the advanced technologies platforms and basic and complex informatics at CHI available for characterization of COVID-19 patient samples, as a priority ahead of our ongoing collaborative studies. The CHI program contributed to two publications and a further four ongoing studies related to COVID-19 during this fiscal year. In collaboration with Dr. John Tsang, CHI performed high-parameter cytometry including staining for antigen-specific cells to investigate the consequences of mild Covid infection in a study which was reported in Nature. In collaboration with Dr. Kalpana Manthiparam, CHI collaboratively worked to generate CITE-seq and analysis cytometry to characterize infection in children and lymph nodes in study which was reported in Nature Immunology. This project has continued as a collaboration from the November 2022 call, to study vaccine responses in children and lymph nodes with CHI taking on an increasing role in CITE-seq data generation (appendix A, study 306). Three further Covid studies have been undertaken under technology development application and partnerships. With Dr. Pamela Guererrio CHI is completing bulk RNA-seq, serum proteomics, and high-parameter color flow cytometry for over 200 samples from a cohort to address adverse reactions to Covid mRNA vaccination (appendix B, study 208). With Dr. Iain Fraser CHI has completed CITE-seq for a study treating Covid infection with Fostamatinib (appendix B, study 314). With Dr Ligia Pinto CHI has completed SomaLogic of 400 samples from the NCI/NIAID SeroNet program characterizing responses after mRNA vaccination (appendix B, study 316). Additional Covid studies that are under discussion for new technology partnerships include studies with Mihalis Lionakis, Pamela Guererrio, and Iain Fraser.